Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Tocilizumab

Nature Reviews Drug Discovery volume 8, pages 273–274 (2009)Cite this article

Abstract

In January 2009, tocilizumab (RoActemra; Chugai/Roche), a humanized monoclonal antibody that binds to the interleukin-6 receptor, was granted marketing authorization by the European Commission for the treatment of moderate to severe rheumatoid arthritis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Smolen, J. S. et al. New therapies for the treatment of rheumatoid arthritis. Lancet 370, 1861–1874 (2007).

    Article  CAS  Google Scholar 

  2. Nishimoto, N. & Kishimoto, T. Interleukin 6: from bench to bedside. Nature Clin. Pract. Rheumatol. 2, 619–626 (2006).

    Article  CAS  Google Scholar 

  3. Sack, U. et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol. Int. 13, 45–51 (1993).

    Article  CAS  Google Scholar 

  4. Madhok, R. et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. 52, 232–234 (1993).

    Article  CAS  Google Scholar 

  5. Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461–468 (1998).

    Article  CAS  Google Scholar 

  6. Takagi N. et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41, 2117–2121 (1998).

    Article  CAS  Google Scholar 

  7. Sato, K. et al. Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res. 53, 851–856 (1993).

    CAS  PubMed  Google Scholar 

  8. European Medicines Agency (EMEA). European Public Assessment Report – RoActemra. EMEA website [online] (2008).

  9. Jones, G. et al. Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 67 (Suppl. II), 89 (2008).

    Google Scholar 

  10. Kremer, J. M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE Study. Arthritis Rheum. 58, 4031 (2008).

    Google Scholar 

  11. Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987–997 (2008).

    Article  CAS  Google Scholar 

  12. Genovese, M. C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968–2980 (2008).

    Article  CAS  Google Scholar 

  13. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516–1523 (2008).

    Article  CAS  Google Scholar 

  14. Mierau, M. et al. Assessing remission in clinical practice. Rheumatology 46, 975–979 (2007).

    Article  CAS  Google Scholar 

  15. Smolen, J. S. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann. Rheum. Dis. 7 Jul 2008 (doi: 10.1136/ard.2008.090019).

    Article  Google Scholar 

  16. IMS MIDAS (2009).

  17. Therapeutic categories outlook: arthritis & inflammation (Cowen and Company, 2008).

Download references

Author information

Authors and Affiliations

  1. Clemens Scheinecker and Josef Smolen are at the Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. clemens.scheinecker@meduniwien.ac.at,

    Clemens Scheinecker & Josef Smolen

  2. Uma Yasothan and Jeffrey Stoll are at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK. josef.smolen@meduniwien.ac.at UYasothan@de.imshealth.com,

    Uma Yasothan & Jeffrey Stoll

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Clemens Scheinecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josef Smolen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey Stoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

J.S. has received honoraria and grant support from Roche, Centocor/Schering-Plough, Abbott, Amgen, Wyeth, Bristol-Myers Squibb and UCB.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheinecker, C., Smolen, J., Yasothan, U. et al. Tocilizumab. Nat Rev Drug Discov 8, 273–274 (2009). https://doi.org/10.1038/nrd2863

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2863

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing